Margaret Tisdale

5.0k citations

64 papers · 4.1k indexed · 1 hit paper · h-index 33

Co-authors: N. R. Parry Brendan Larder Sharon D. Kemp Richard Myers Barbara Maschera Edward D. Blair G. Darby Diane J. Cousens
Topics: HIV Research and Treatment (41 papers)HIV/AIDS drug development and treatment (39 papers)HIV/AIDS Research and Interventions (17 papers)
Cited by: Virology Infectious Diseases Epidemiology
Journals: Nature Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: United Kingdom United States Netherlands

In The Last Decade

Margaret Tisdale

63 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

1993 523 citations Margaret Tisdale, N. R. Parry et al. profile →

Peers

Countries citing papers authored by Margaret Tisdale

Since Specialization

Citations

This map shows the geographic impact of Margaret Tisdale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret Tisdale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret Tisdale more than expected).

Fields of papers citing papers by Margaret Tisdale

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret Tisdale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret Tisdale. The network helps show where Margaret Tisdale may publish in the future.

Co-authorship network of co-authors of Margaret Tisdale

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret Tisdale. A scholar is included among the top collaborators of Margaret Tisdale based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret Tisdale. Margaret Tisdale is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques 2008 ·Antiviral Research ·Koert J. Stittelaar,Margaret Tisdale,(unknown),(unknown),F.H.M. Pistoor,James H. Simon,Albert D. M. E. Osterhaus	30
2	Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial 2007 ·Clinical Therapeutics ·Craig LaForce,Choy Man,Frederick W. Henderson,Janet E. McElhaney,Frank C. Hampel,Robert Bettis,(unknown),Julia Harris,Philip Yates,Margaret Tisdale,Alison Webster	43
3	Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance 2004 ·AIDS ·Lisa Ross,Neil Parkin,Colombe Chappey,(unknown),Marty St. Clair,Michael Bates,Margaret Tisdale,E. Randall Lanier	35
4	Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens 2004 ·HIV Medicine ·(unknown),Naomi Givens,Christopher Stone,Philip Griffin,Diana M. Gibb,Sarah Walker,Margaret Tisdale,David M. Irlbeck,Mark Underwood,Marty St. Clair,Mounir Ait‐Khaled	30
5	M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine 2002 ·AIDS ·Mounir Ait‐Khaled,Christopher Stone,(unknown),Bonaventura Clotet,Schlomo Staszewski,Christine Katlama,Margaret Tisdale	41
6	Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro 2002 ·Journal of Virology ·Michael Maguire,Rosario Guinea,Philip Griffin,(unknown),Robert C. Elston,(unknown),(unknown),Mary H. Hanlon,David Porter,Terri Wrin,Neil Parkin,Margaret Tisdale,Eric S. Furfine,C. Petropoulos,(unknown),Jőrg‐Peter Kleim	117
7	Characterization of 2 Influenza A(H3N2) Clinical Isolates with Reduced Susceptibility to Neuraminidase Inhibitors Due to Mutations in the Hemagglutinin Gene 2002 ·The Journal of Infectious Diseases ·Yacine Abed,Anne–Marie Bourgault,Robert J. Fenton,Peter J. Morley,David Gower,Ian J. Owens,Margaret Tisdale,Guy Boivin	49
8	A Phase II Trial of Dual Protease Inhibitor Therapy: Amprenavir in Combination With Indinavir, Nelfinavir, or Saquinavir 2001 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown),Richard Haubrich,William Lang,(unknown),Judith Millard,(unknown),Wendy Snowden,Louise Pedneault,Margaret Tisdale	15
9	HIV Type 1 Protease Cleavage Site Mutations and Viral Fitness: Implications for Drug Susceptibility Phenotyping Assays 2000 ·AIDS Research and Human Retroviruses ·(unknown),Richard Myers,(unknown),Margaret Tisdale,Edward D. Blair	49
10	HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy 2000 ·AIDS ·Veronica Miller,Mounir Ait‐Khaled,Christopher Stone,Philip Griffin,(unknown),Amy Cutrell,(unknown),(unknown),Christine Katlama,Gillian Pearce,Margaret Tisdale	107
11	Development of a Sensitive Chemiluminescent Neuraminidase Assay for the Determination of Influenza Virus Susceptibility to Zanamivir 2000 ·Analytical Biochemistry ·(unknown),Brooks S. Edwards,(unknown),John C. Voyta,Margaret Tisdale,Richard C. Bethell	108
12	Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors 2000 ·Reviews in Medical Virology ·Margaret Tisdale	121
13	A Novel Genotype Encoding a Single Amino Acid Insertion and Five Other Substitutions Between Residues 64 and 74 of the HIV-1 Reverse Transcriptase Confers High-Level Cross-Resistance to Nucleoside Reverse Transcriptase Inhibitors 1999 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown),Mounir Ait‐Khaled,Philip Griffin,Deborah A. Thomas,Margaret Tisdale,Jőrg‐Peter Kleim	19
14	In Vitro Selection and Characterisation of Influenza B/Beijing/1/87 Isolates with Altered Susceptibility to Zanamivir 1999 ·Virology ·Jacqueline M. Barnett,(unknown),(unknown),(unknown),Andrew Lewis,Margaret Tisdale,Richard C. Bethell	63
15	Pharmacodynamics of 141W94 as determined by short term change in HIV RNA Influence of viral isolate baseline EC50 1997 ·George L. Drusano,Brian M. Sadler,Judith Millard,William T. Symonds,Margaret Tisdale,(unknown),Alan Bye	4
16	In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents 1996 ·Antiviral Research ·M H St Clair,Judith Millard,John P. Rooney,Margaret Tisdale,N. R. Parry,Brian M. Sadler,Martin Blum,George R. Painter	65
17	Human Immunodeficiency Virus 1996 ·Journal of Biological Chemistry ·Barbara Maschera,G. Darby,Giorgio Palù,Lois L. Wright,Margaret Tisdale,Richard Myers,Edward D. Blair,Eric S. Furfine	300
18	Purine 2'-deoxy-2'-fluororibosides as antiinfluenza virus agents 1993 ·Journal of Medicinal Chemistry ·Joel V. Tuttle,Margaret Tisdale,Thomas A. Krenitsky	53
19	Monoclonal Antibodies Define Linear and Conformational Epitopes of HIV-1 pol Gene Products 1991 ·AIDS Research and Human Retroviruses ·(unknown),(unknown),Margaret Tisdale,(unknown),Richard S. Tedder	17
20	Mutations within the RNase H Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Abolish Virus Infectivity 1991 ·Journal of General Virology ·Margaret Tisdale,Tobias Schulze,(unknown),Karin Moelling	129

About Margaret Tisdale

Margaret Tisdale is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 64 papers that have together received 4.1k indexed citations. Recurring topics across this work include HIV Research and Treatment (41 papers), HIV/AIDS drug development and treatment (39 papers) and HIV/AIDS Research and Interventions (17 papers). The work is most often cited by research in Virology (2.4k citations), Infectious Diseases (2.8k citations) and Epidemiology (1.3k citations). Margaret Tisdale has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include N. R. Parry, Brendan Larder, Sharon D. Kemp, Richard Myers, Barbara Maschera, Edward D. Blair, G. Darby, Diane J. Cousens, J. W. T. Selway and Eric S. Furfine. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact